Table 1.
Biological and sleep markers before and after treatment with 5–OH tryptophan
| Before Treatment | After Treatment | |
|---|---|---|
| Epworth sleepiness score, 0–24 | 18 | 9 |
| Sleep duration/24 h log, min | 704 ± 180 | 540 ± 76 |
| Sleep/wake period, h | 11.8 ± 5.3 | 24 ± 1.7 |
| Body mass index, kg/m2 | 31.2 | 26.3 |
| Intestinal transit time, h | 22h22 | 10h48 |
| Polysomnography (2 nights/period) | ||
| Sleep onset latency, min | 56–75 | 23–39 |
| REM sleep latency, min | 51–65 | 113–232 |
| Night–time total sleep time, min | 452–489 | 531–533 |
| Sleep efficiency, % | 76.6–87.8 | 68.2–81.7 |
| Total sleep time/24 h, min | 533–700 | 531–603 |
| Stage N1, % | 11–l;11.5 | 10.5–14.6 |
| Stage N2, % | 48.5–53.5 | 54.7–60.9 |
| Stage N3, % | 14.5–14.6 | 10.6–11.2 |
| REM sleep, % | 20.5–26 | 18–20.2 |
| Arousal, No/h | 11.7–11.8 | 6.4–7.2 |
| Apnea–hypopnea, No/h | 0.9 | 1.6 |
| Periodic leg movements, No/h | 0 | 0.1 |
| CSF biological markers | ||
| 5–hydroxyindolacetic acid, nmol/L Range: 65–200, NV: 130 | 45 | 100 |
| Homovanillic acid, nmol/L Range: 150–400, NV: 250 | 30 | 170 |
| Neopterin, nmol/L Range: 9–28, NV: 18 | 67 | 43 |
| Total biopterins, nmol/L Range: 12–35, NV: 17 | 47 | 77 |
| Sepiapterin, nmol/L NV: not detected, < 0.3 nmol/L | 6 | 11 |
NV, normal value; ND, not detected (< 0.3 nmol/L);
major differences in bold